Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand

Stock Track

03/03

BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.

The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.

Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1139657449"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139657449\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139657449?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139657449","market":"nz","top_or_hot":-1,"title":"Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand","media":"Stock Track","content":"<p>BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.</p><p>The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.</p><p>Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-03 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.</p><p>The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.</p><p>Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1139657449","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139657449","pubTimestamp":1772549849,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.The decline follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州"},"translate_title":"个股追踪|品牌重塑后估值担忧BeOne Medicines盘中暴跌5.34%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1},"content_text":"BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}